Inhibition of c-Fos expression attenuates IgE-mediated mast cell activation and allergic inflammation by counteracting an inhibitory AP1/Egr1/IL-4 axis

Hui-Na Wang  
Shenzhen University

Kunmei Ji  
Shenzhen University

Li-Na Zhang  
Shenzhen University

Chu-Chu Xie  
Shenzhen University

Wei-Yong Li  
Shenzhen University

Zhen-Fu Zhao  
Shenzhen University

Jia-Jie Chen (chenjj@szu.edu.cn)  
Shenzhen University  https://orcid.org/0000-0002-1372-8450

Research Article

Keywords: mast cells, FcεRI signaling, c-Fos, Egr1, T-5224

DOI: https://doi.org/10.21203/rs.3.rs-297872/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** Activator protein-1 (AP1), a c-Fos–JUN transcription factor complex, mediates many cytobiological processes. c-Fos has been implicated in immunoglobulin (IgE) activation of mast cells (MCs) via high-affinity IgE Fc receptor (FcεRI) binding. This study examined c-Fos involvement in MC activation and tested the effects of the c-Fos/AP1 inhibitor T-5224 on MCs activation and allergic responses.

**Methods:** *In vitro* studies were conducted with two MC model systems: rat basophilic leukemia cells (RBLs) and mouse bone marrow derived mast cells (BMMCs). MC degranulation and effector functions were examined with β-hexosaminidase release and cytokine secretion assays. c-Fos/AP1 was inhibited with T-5224. c-Fos activity was suppressed with short hairpin RNA targeting c-Fos (shFos). *In vivo* immune responses were evaluated in passive cutaneous anaphylaxis (PCA) and ovalbumin-induced active systemic anaphylaxis (ASA) models, as well as in an oxazolone (OXA)-induced model of atopic dermatitis, a common allergic disease.

**Results:** c-Fos expression was elevated transcriptionally and translationally in IgE-stimulated MCs. c-Fos binding of the *Egr1* (early growth response 1) promoter upregulated *Egr1* transcription, leading to production of interleukin (IL)4. T-5224 reduced FcεRI-mediated MC degranulation (evidenced by β-hexosaminidase activity and histamine levels) and diminished EGR1 and IL4 expression. T-5224 attenuated IgE-mediated allergic responses in PCA and ASA models, and it suppressed MC-mediated atopic dermatitis in mice.

**Conclusion:** IgE binding can activate MCs via a c-Fos/Egr1/IL-4 axis. T-5224 suppresses MC activation *in vitro* and *in vivo* and thus represents a promising potential strategy for targeting MC activation to treat allergic diseases.

Introduction

Allergic diseases are disruptive to quality of life, can cause serious morbidity, and their incidence has been on the rise[1]. Mast cells (MCs) play a key role in immunoglobulin (Ig)E mediated allergic reactions[2]. Binding of high-affinity IgE Fc receptors (FcεRIs) on the surface of MCs by antigen (Ag)-linked IgE antibodies activates the IgE/FcεRI pathway, which promotes cellular degranulation and the release of cytoinflammatory factors[3, 4]. FcεRI aggregation induces phosphorylation of a linker molecule[5] and a signaling cascade involving Bruton's tyrosine kinase, phospholipase γ, and protein kinase C[6], leading to activation of downstream signaling pathways—including calcium signaling[7, 8], mitogen-activated protein kinase (MAPK)[9] and nuclear factor κB[10] pathways—which initiate MC degranulation and cytokine production.

Elucidating molecular mechanisms that modulate MC activation could provide crucial insights into the pathophysiology of allergic diseases. Recently, FcεRI-stimulated MC activation and anaphylaxis were shown to be dampened by antagonism of an orphan nuclear receptor called nuclear receptor subfamily 4
group A member 1, which acts in opposition to the anti-inflammatory liver kinase B1/adenosine monophosphate-activated protein kinase axis[11]. In addition, FcεRI-mediated MC activation has been shown to be negatively regulated by regulator of calcineurin 1 [12].

Activator protein-1 (AP-1)—a transcription factor complex formed by dimerization of c-Fos, a leucine zipper protein, with c-Jun—modulates signaling pathways involved in many cytobiological processes, including proliferation, differentiation, transformation, and cell death[13]. AP-1–dependent regulation of cytokine transcription requires the presence of c-Fos[14], and IgE/Ag treatments upregulate c-Fos transcription in MCs[15, 16]. In c-Fos–deficient MCs, FcεRI-mediated degranulation can be inhibited by down-regulation of degranulation genes[13, 17]. Experiments examining anaphylactic processes have shown that released cytokines can induce AP-1–dependent MC secretion of interleukin (IL)6 consequent to activation of the IL6 gene promoter[18]. The molecular mechanism by which FcεRI activation leads to upregulation of c-Fos expression has not been clarified. Moreover, clinical translation studies of the effects of c-Fos/AP-1 inhibition on IgE/Ag-activated MCs and allergic responses are needed.

Here, we used next-generation RNA sequencing (RNA-Seq) and real time quantitative reverse transcriptase (qRT)-polymerase chain reaction (PCR) to analyze the MC transcriptional response to IgE/Ag activation. We identified MC activation-associated proteins that interact with c-Fos, including early growth response (EGR), IL, and chemokine (C-C motif) ligand (CCL) proteins[19, 20]. We were particularly interested in the potential involvement of EGR1 because it regulates IL-4 secretion in FcεRI-activated MCs[21]. We conducted qRT-PCR and western blotting to measure Egr1 expression levels in stimulated MCs, with and without anti-Fos silencing short hairpin RNA (ShFos). To explore the intracellular mechanism of c-Fos involvement in MC activation, we examined the effects of the c-Fos/AP-1 inhibitor T-5224 on inflammatory cytokine expression and MAPK signaling. Finally, we examined T-5224 effects on MC activation responses in in vivo models.

Materials And Methods

Reagents

T-5224 (PubChem CID: 23626877) was purchased from TargetMol (Shanghai, China). Monoclonal DNP-specific IgE, DNP-HSA, and 4-nitrophenyl N-acetyl-β-D-glucosaminide were obtained from Sigma-Aldrich (St. Louis, MO). Aluminum adjuvant was purchased from Thermo Scientific (Waltham, MA). Evans blue, ketotifen fumarate (PubChem CID: 5282408), formamide and toluidine blue were purchased from Meilun Biotechnology Co., Ltd (Dalian, China).

Animals

Female Balb/c mouse pups were used in accordance with ethical protocols. Female Balb/c mice (6–8 wks, 18–20 g) from Guangdong Medical Laboratory Animal Center (Benxi, Liaoning, China) were bred in an aseptic-specified pathogen-free environment with controlled humidity (55 ± 10%) and temperature (24 ± 1°C). Animal experiments were carried out according to protocols approved by our University's Animal
Care and Use Committee and in compliance with the Guidelines on Animal Welfare of the School of Medicine of Shenzhen University. Mouse health was monitored twice daily, and early humane euthanasia was conducted in cases of weight loss > 15% body weight, lethargy, inability to stand, or anorexia.

**Cell culture**

Rat basophilic leukemia cells (RBLs; RBL-2H3 cell line from Cellcook Biotechnology, Guangzhou, China) were cultured in complete Dulbecco’s modified Eagle medium with 4.0 mM L-glutamine, sodium pyruvate, 100 U/ml penicillin, 100 µg/ml streptomycin, non-essential amino acid (Solarbio, Beijing, China) and 10% fetal bovine serum (Gibco, Grand Island, NY) in a humidified incubator at 37°C, 5% CO₂.

**Preparation of BMMCs**

BMMCs were isolated from 6–8-week-old female Balb/c mouse femurs. The animals were euthanized with CO₂ and submerged in 70% ethanol; then intact femurs were removed. Sterile endotoxin-free medium was flushed through bone shafts repeatedly with a syringe and needle. A suspension of collected bone marrow cells was centrifuged (300 × g, 5 min). The spun-down cells were cultured (0.5 × 10⁶ nucleated cells/ml) in RPMI 1640 media supplemented with 10% fetal bovine serum, penicillin (100 U/ml), streptomycin (100 µg/ml), sodium pyruvate (10 mM), L-glutamine (2 mM), 4-(2-hydroxyethyl)-piperazine ethane sulfonic acid (10 mM), and recombinant stem cell factor and IL-3 (10 ng/ml each). After ~ 5 weeks in culture, BMMC purity was ~ 95%, as determined by flow cytometry of cell-surface CD117 and FcεRI[22].

**Cytotoxicity**

Cell viability was evaluated with a Cell Counting Kit 8 assay kit (MedChem Express, Monmouth Junction, NJ). RBLs (2 × 10³ /well) and BMMCs (1 × 10⁴ /well) were each cultured in 96-well plates and incubated with T-5224 for 24 h. Kit-provided solution was added wells and incubated at 37°C for 1 h. Absorbance at 450 nm was detected by a multi-well plate reader (Bio-Rad, Hercules, CA). Viability was calculated as relative absorbance expressed as a percentage of control values.

**β-hexosaminidase release**

β-hexosaminidase release served as a MC degranulation index[23]. Dinitrophenol (DNP)-targeting IgE (50 ng/mL)-sensitized RBLs or BMMCs were pretreated with T-5224 for 1 h. After two phosphate buffered saline (PBS) washes, cells were stimulated with DNP-HSA (100 ng/ml) for 30 min at 37°C. Supernatant aliquots (50 µL) were transferred to 96-well plates and incubated with an equal volume of substrate solution (1 mM 4-nitrophenyl-N-acetyl-β-d-glucosaminide) for 90 min at 37°C. To obtain total β-hexosaminidase release, cells in control wells were lysed with 0.1% Triton X-100 before plate reading. The reaction was terminated with 150 µl of stop solution (0.1 M Na₂CO₃ and NaHCO₃). Absorbance at 405 nm was detected by a multi-well plate reader (Bio-Rad, Hercules, CA).

**RNA-Seq**
RNA-seq was performed with a BGISEQ-500 sequencer (Beijing Genomics Institute, Beijing, China)[24]. Total RNA was extracted from RBLs with Trizol. The sequencing data were filtered with SOAPnuke (v1.5.2)[25] by removing reads that contained the sequencing adapter or had a low-quality (< 5) base ratio > 20%. The remaining clean reads were stored in FASTQ format and mapped to the reference genome using HISAT2 (v2.0.4)[26]. The reads were aligned in RSEM (v1.2.12) with Bowtie (v2.2.5)[27]. Differential expression was analyzed with DESeq2 (v1.4.5)[28], and gene expression heatmaps were drawn in heatmap (v1.0.8). Our RNA-seq data were deposited in GEO (accession GSE161317).

**Real-time qRT-PCR**

Total cellular RNA was isolated with an RNeasy Mini Kit (Qiagen, Duesseldorf, Germany) and reverse transcribed into cDNAs with a TIAN Script II RT Kit (Tiangen Biotech, Beijing, China) and primers (Figure Table 1) according to the manufacturer's instructions. Real-time qRT-PCRs were performed with TB Green® Premix ExTaq™ (Takara, Tokyo, Japan) in a qTOWER 2.2 system (Analytik Jena, Upland, CA). Expression levels were computed by normalizing relative to GAPDH (glyceraldehyde 3-phosphate dehydrogenase) mRNA levels with the $2^{-\Delta\Delta Ct}$ technique. The primers were shown in Table S1.

**Western blotting**

Cell lysate preparation and immunoblotting were performed as previously described [29]. Anti-DNP IgE (50 ng/ml)-sensitized RBLs (5 × 10^5/well in 6-well plates) were pretreated with T-5224 for 1 h and then stimulated with DNP-HSA for 4 h (p–c-Fos FRA1, and EGR1) or 30 min (others). The cells were washed with PBS twice and lysed with 200 µl RIPA buffer containing protease inhibitor cocktail (MedChem Express, Monmouth Junction, NJ). Lysed samples were cooled on ice for 15 min and centrifuged at 12,000 rpm for 10 min at 4°C. Protein concentrations were measured with a BCA kit (Beyotime, Beijing, China). Equal amounts of lysate were separated by 10% sodium dodecyl sulfate–polyacrylamide-gel electrophoresis and transferred to polyvinylidene difluoride membranes.

Membranes were incubated with primary antibodies at 4°C, and then incubated with horse radish peroxidase-conjugated anti-rabbit antibody for 1 h at room temperature. The following rabbit antibodies were purchased from Cell Signaling Technology (Danvers, MA) and applied at 1:1000 dilutions: p-p44/42 MAPK (ERK1/2) (#4370, Thr202/Thr204, monoclonal); p44/42 MAPK (ERK1/2) (#4695, monoclonal); JNK (#9252, polyclonal); p-JNK (Thr183/Tyr185) (#4668, monoclonal); p38 (#8690, monoclonal); p-p38 (#4511, monoclonal), the following rabbit monoclonal antibodies were purchased from Abcam (Cambridge, MA, USA): c-Fos (ab134122, 1:2000), FosB (ab184938, 1:10,000) and EGR1 (ab133695, 1:2000). Mouse anti-GAPDH monoclonal antibody (sc-365062) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA)(1:1000). Second antibodies included anti-rabbit (#7074, 1:5000) and anti-mouse (#7076, 1:5000) IgG-horseradish peroxidase (HRP) were both from Cell Signaling Technologies., Inc. Protein bands were visualized using the enhanced chemiluminescence (Meilun, Dalian, China) and analyzed using ImageJ software (ImageJ 1.80v; National Institutes of Health, Bethesda, MA, USA).

**Chromatin immunoprecipitation (ChIP)**
RBLs were collected as previously described [30]. Proteins were crosslinked to DNA by adding 270 µl of 37% formaldehyde to 10 ml culture medium (final concentration, 1%). After 10-min incubations at 37°C, reactions were quenched by adding 0.125 M glycine for 5 min at room temperature. After washing with ice-cold PBS twice, fixed cells were lysed with 1 ml RIPA buffer (MedChem Express, Monmouth Junction, NJ) on ice for 10 min. After centrifugation, nuclei were sonicated (30% amplitude, 20 sets of 15-s bursts) for four rounds. Debris was removed by centrifugation at 13,000 rpm at 4°C for 10 min; supernatants were transferred to new tubes. Lysates were precleared with protein A/G beads before being incubated with c-Fos antibodies (Cell Signaling Technology, Danvers, MA) or IgG (Santa Cruz, CA) at 4°C overnight with rotation. The immunocomplex was washed (once each) in low salt, high salt, and LiCl solutions and washed twice in TE buffer. Bead-bound immunocomplexes were eluted with 200 µl elution buffer. To reverse histone-DNA crosslinks, samples were combined with 5 M NaCl and heated at 65°C for 4 h. DNA product was purified in a spin column system (Omega Bio-Tek, Norcross, GA).

**Knockdown of c-Fos**

We cloned shFos (5′-GCAGACCGAGATTGCCAATTT-3′) and GFP mRNA as a negative control (shNC, 5′-GCAAGCTGACCCTGAAGTTCAT-3′) into pLKO.1-puro vectors (Sigma, St. Louis, MO). Sequences were confirmed by DNA sequencing (Beijing Genomics Institute, Shenzhen, China). Liposomes (Bioinno-Profei Tech, Qingdao, China) were applied to enable cell transfection.

**Dual luciferase promoter-reporter assay**

Transient transfection was conducted with liposome transfection reagent. RBLs were seeded in 24-well plates and transfected with the AP-1 luciferase-reporter plasmid pAP1-Luc (Promega, USA), and compared to control plasmid pGL3-basic or pGL3-control. Activities of Firefly luciferase in pGL3-reporters and Renilla luciferase in pRL-TK were determined 48 h later by dual luciferase reporter assays following the manufacturer’s protocol (Promega, Madison, WI). Each transfection was performed in triplicate and each assay was repeated at least three times.

**IgE-mediated passive cutaneous anaphylaxis (PCA) mouse model**

A PCA mouse model was used to assess T-5224 effects on allergic reactions [31]. In this model, extravasation reflects vessel permeability. Twenty-four mice were randomized into four groups (6/group): PBS; DNP-HSA; DNP-HSA plus T-5224; and DNP-HSA plus ketotifen. Left ears were injected subcutaneously with anti-DNP IgE (500 ng in 0.9% saline). Twenty-four hours later, IgE-sensitized mice were given an intraperitoneal (i.p.) injection of T-5224 (60 mg/kg) or ketotifen (50 mg/kg), and 1 h later challenged with a tail vein injection of 200 µg of DNP-HSA in 1× PBS with 0.5% Evans blue dye. Mice were euthanized 1 h after the challenge; their ears were removed and dissolved in 700 µl formamide overnight at 62°C. Extravasated dye was quantitated with 620-nm spectrophotometry (Bio-Rad, Hercules, CA).
**Ovalbumin (OVA)-induced active systemic anaphylaxis (ASA) mouse model**

The OVA-induced ASA model is widely used to examine immediate-type hypersensitivity, which is strongly associated with MCs [32]. A cohort of 24 mice was randomized into four groups (6/group): Negative control; OVA sensitization/challenge; OVA sensitization/challenge plus T-5224; and OVA sensitization/challenge plus ketotifen (50 mg/kg). The mice were sensitized on days 0 and 7 with OVA (100 µg i.p. with 2 mg alum adjuvant). From experimental day 9 to 13, mice received T-5224 (60 mg/kg) and ketotifen (50 mg/kg), i.p. on alternating days. On day 14, the mice were challenged with 200 µg OVA (i.p.) and then monitored for 90 min, during which their rectal temperatures were measured every 10 min. Immediately thereafter, orbital venous plexus blood was sampled for serum histamine and IL-4 level measurement by enzyme-linked immunosorbent assay (ELISA).

**Oxazolone (OXA)-induced atopic dermatitis model**

In the OXA-induced atopic dermatitis model, massive inflammatory cell infiltration leads to skin thickening [33]. To produce the model [34], the right ears of Balb/c mice were sensitized with 20 µL of 1% OXA (TargetMol, Shanghai, China) in 4:1 (v/v) acetone-olive oil mixture (experimental day 0). Plain acetone/sesame seed oil was injected in the left ears to obtain within-animal controls. On days 7, 9, and 11, the ears were challenged with 20 µL of 1% OXA three times a week for 1 wk. At the same time, T-5224 (60 mg/kg, i.p.) was administered. On day 13, the mice were sacrificed, ear samples were collected for further analysis. Ear swelling change was used as a measure of allergic response.

**Cytology and histology**

Cell staining methods are described in the Supplemental information. Cells were examined under a light microscope (Carl Zeiss, Goettingen, Germany) to view staining and to detect morphological changes associated with MC degranulation, particularly F-actin cytoskeleton decomposition [35]. Mouse ears were fixed in a 4% paraformaldehyde (Solarbio, Beijing, China) and embedded in paraffin. Sections were cut (thickness, 4 mm), dewaxed, cleared in xylene, hydrated, and stained with hematoxylin and eosin (H&E; Seivicebio, Wuhan, China) to visualize epidermal thickness and eosinophils, and with toluidine blue (Seivicebio, Wuhan, China). Eosinophils and MCs were counted in five randomly selected images.

**Histamine and IL4 release**

BMMCs were sensitized with anti-DNP IgE (50 ng/ml) overnight, pretreated with T-5224 for 1 h, and then stimulated with DNP-HSA for 30 min (for histamine detection) or 6 h (for IL-4 detection). Cell suspensions were centrifuged (300 × g, 5 min) to separate cells from media. Supernatant concentrations of histamine and IL4 were determined with enzyme-linked immunosorbent assay (ELISA) kits for mouse histamine (IBL, Hamburg, German) and mouse IL4 (Shanghai Hu Zhen Biological Technology, Shanghai, China).

**Statistical analyses**
All clinical and histological evaluations were performed in a blinded manner. Data were analyzed in Prism 8 (GraphPad, La Jolla, CA). For normally distributed quantitative variables, means of triplicate values are reported with standard deviations (SDs). Kruskal–Wallis tests were performed to detect significant differences between treatment groups. One-way analyses of variance (ANOVAs) and Dunnett's post-hoc tests were used to find differences between treatment groups in the in vivo experiments. Differences was considered significant at $p < 0.05$.

**Results**

c-Fos expression is elevated in IgE-stimulated MCs

In IgE-activated RBLs, DNP-HSA triggered the release of the granule-related mediator β-hexosaminidase ($p < 0.01$; Fig. 1A) and increased transcription of inflammatory cytokine genes associated with type I hypersensitivity reactions, namely TNF, CCL2, and IL4 (all $p < 0.01$; Fig. 1B–D), affirming the establishment of a MC activation model. In non-stimulated MCs, RNA-seq revealed 191 differentially expressed genes (DEGs; $Q \leq 0.05$) following DNP-HSA treatment. Among them, 116 were upregulated (61%) and 75 were down-regulated (39%; Figure S1). The top 36 upregulated genes are shown in Fig. 1E. Functional enrichment analysis indicated that there were functionally distinct modules within each group (Figure S2&S3).

RT-qPCR assays demonstrated increased mRNA levels of cFos (Fig. 1F) and FosB (Fig. 1G) in stimulated RBLs (both $p < 0.01$), with unchanged Fosl1 (Fig. 1H) and Fosl2 (Fig. 1I) levels (both $p > 0.05$). Western blotting showed that activated MCs had significantly upregulated c-Fos and FosB after treatment with DNP-HSA (Fig. 1J), together with increased phosphorylation of c-Fos at Ser32 (Fig. 1J).

c-Fos upregulates EGR1 transcription through EGR1 promoter binding

Network analysis suggested c-Fos protein-protein interactions with a number of MC activation-associated proteins, including early growth response 1 (Egr1), Egr2, Egr3, IL-4, and Ccl2 (Fig. 2A). Subsequently, qRT-PCR and western blot analyses showed that IgE/Ag-stimulated MCs had increased Egr1 mRNA and EGR1 protein levels, compared to non-stimulated MCs (Fig. 2B, C), consistent with our RNA-Seq data. Treatment with shFos decreased EGR1 mRNA and protein levels, compared to non-treated controls (NCs) (Fig. 2D&E). To verify that EGR1 is activated by c-Fos in MCs, we obtained the first three Fos-binding sequences within the Egr1 promoter from JASPAR (Fig. 2F). A ChIP assay confirmed that Fos binds the Egr1 promoter (Fig. 2G).

Inhibition of c-Fos/AP1 attenuates IgE-mediated MC activation in vitro

The chemical structure of T-5224, a selective c-Fos/AP1 inhibitor, is shown in Fig. 3A. Cell viability assays showed that 50 μM T-5224 exposure for 24 h did not have cytotoxic effects on RBLs (Fig. 3B). Thus, we used ≤ 50 μM T-5224 for our in vitro experiments. Luciferase reporter (Luc) assays performed to detect off-target versus selective AP1-inhibitory effects showed that T-5224 reduced AP1-Luc activity (Fig. 3C).
In DNP-HSA–activated RBLs, T-5224 reduced β-hexosaminidase release (IC$_{50}$: 18.30 ± 1.48µM; Fig. 3D) and suppressed IL4 release (Fig. 3E). T-5224 reduced activation-associated cytomorphological changes, including elongation and F-actin decomposition (Figure S4).

Regarding AP1-inhibition effects on MC activation signaling, qRT-PCR and western blot analyses showed that T-5224 pretreatment decreased transcription and translation of EGR1 in IgE-stimulated RBLs, with the effect being stronger with the high dose (20 µM) than with the low dose (10 µM) (Fig. 3F&G). Western blot analysis showed that T-5224 inhibited activation of MAPKs (p38, JNK, and ERK) in activated RBLs, as evidenced by decreased levels of p-p38, p-JNK and p-ERK1/2 (Fig. 3H), with the high dose resulting in more pronounced reductions.

T-5224 (0.1–50 µM) did not affect BMMC viability (Fig. 4A). T-5224 inhibited release of β-hexosaminidase (IC$_{50}$: 14.51 ± 0.44µM; Fig. 4B) and histamine (Fig. 4C) in IgE/Ag-stimulated BMMCs. T-5224 pretreatment reduced IL4 mRNA, IL4 protein, and Egr1 mRNA expression with the high-dose treatment producing more pronounced effects than the low-dose treatment (Fig. 4E–G). Concomitantly, T-5224 pretreatment inhibited activation of all three MAPK pathways (Fig. 4F).

**T-5224 inhibits IgE-mediated PCA *in vivo***

As shown in Fig. 5, IgE/Ag stimulation induced robust *in vivo* PCA reactions, evidenced by dye diffusion, ear thickening, and dye extrusion from injected ears. T-5224 attenuated these responses, as shown by decreased dye diffusion (Fig. 5A,B), reduced ear thickness (Fig. 5C), and diminished dye extrusion (Fig. 5D) compared to the activated group not given T-5224. The effects of T-5224 resembled those of the anti-allergy drug ketotifen.

**T-5224 attenuates MC-induced allergic reaction in OVA-induced ASA model**

To establish the OVA-induced allergy model (Fig. 5E), mice were sensitized with repeat administrations of OVA Ag plus alum adjuvant; then an allergic reaction was induced with an OVA challenge (Fig. 5E). During the 90-min post-OVA challenge period, rectal temperatures of control mice decreased over 40 ~ 50 min, and then recovered. This reduction was attenuated by injection of T-5224 or ketotifen (positive control) (Fig. 5F). Notably, 80 min after the challenge induction, the mean rectal temperature for the OVA-sensitized group remained low (29.36 ± 0.93°C) whereas that of the T5224-treated OVA-sensitized group (34.60 ± 0.83°C) was similar to that of non-sensitized controls. Concomitantly, serum histamine levels increased after the OVA challenge (non-sensitized control group, 1126 ± 81 ng/ml) and this increase was diminished significantly by T-5224 (211 ± 122 ng/ml) (Fig. 5G&H).

**T-5224 suppresses OXA-induced atopic dermatitis symptoms in mice**

The atopic dermatitis model mice exhibited marked ear skin thickening and these dermatitis symptoms were attenuated by T-5224 ($p<0.01$; Fig. 6A, B). Toluidine blue staining showed that the infiltration of mast cells in the dermis was observed in the dermis of the control group. The number of mast cells in the
ear dermis was decreased significantly after T-5224 treatment ($p < 0.01$; Fig. 6C, D). In addition, increased the permeability of blood vessels in allergic skin allowed eosinophils to infiltrate into tissue. H&E staining revealed that eosinophil infiltration of the ear skin was attenuated by treatment in the T-5224 groups compared with the AD group ($p < 0.01$; Fig. 6E, F). The results indicated T-5224 had a protective effect against OXA-induced AD in mice.

**Discussion**

We confirmed that DNP-HSA triggered MC degranulation, as evidenced by β-hexosaminidase release and upregulation of allergic reaction-related genes, thereby confirming the validity of our IgE-activated RBL model of activated MCs[36]. Transcriptome analysis revealed that cFos and FosB were upregulated by DNP-HSA stimulation of RBLs. Stimulated RBLs had increased c-Fos phosphorylation. Inhibition of c-Fos/AP1 with T-5224 reduced degranulation, suppressed MC activation-associated morphological changes, and attenuated MC activation effects on IL4 and EGR1 expression. IgE/Ag-stimulated MCs showed upregulation of EGF1, both transcriptionally and translationally, that could be attenuated by suppression of c-Fos activity. We demonstrated in a ChIP assay that Fos bound the Egr1 promoter region, indicating that Egr1 transcription was likely activated by c-Fos binding its promoter during MC activation. Furthermore, T-5224 pretreatment decreased EGF1 transcription and translation and inhibited MAPK activation in activated MCs. Finally, in multiple models, T-5224 had a protective effect against the development of allergic responses including swelling, body temperature reduction, histamine release, and infiltration of MCs and eosinophils.

MCs represent a potential therapy target to alleviate allergic reactions[37]. Extending prior findings implicating Fos in IgE/FcεRI-activated MCs[13], we demonstrated that IgE/Ag treatment enhances c-Fos transcription and translation, and that c-Fos acts on the Egr1 promoter to upregulate EGR1 expression. EGR1 is a zinc-finger transcription factor that regulates the expression of various inflammatory cytokines following FcεRI activation, including TNF, IL6, IL13, and IL4[38, 39].

Previously, EGR1 was shown to induce IL4 secretion in FcεRI-activated MCs by binding the Il4 promoter[21]. IL4 enhances IgE-mediated MC responses and is a necessary mediator of allergy development[20, 40]. IL4 is critical for directing Th2 cell differentiation and B cell antibody class switching to allergenic IgEs[41]. FcεRI-mediated MC-derived IL4 production is important for allergy pathogenesis[42]. Our results indicating that c-Fos binding of the Egr1 promoter can drive EGR1 expression are consistent with a new cFos/Egr1/IL-4 axis of MC activation.

AP1 activity is positively associated with the development of IgE-mediated allergic diseases, and AP1 inhibition can suppress allergic asthma symptoms[43–46]. To examine the allergenic role of AP1, we employed T-5224, a selective c-Fos/AP1 inhibitor produced by Aikawa et al. based on the crystal structure of the AP1-DNA complex[47]. T-5224 has been shown to suppress collagen-induced arthritis[47], lipopolysaccharide-induced liver/kidney injury[48, 49], intervertebral disc degeneration and associated
pain[50], and breast cancer[51]. However, it was not known whether T-5224 may impede MC-induced allergic responses.

Our results showing that T-5224 reduced FcεRI-mediated degranulation in MCs were similar to previously reported effects of palbociclib (cyclin-dependent kinase inhibitor) and tozasertib (Aurora kinase inhibitor) [22, 52]. Mechanistically, T-5224 decreased IgE/Ag-induced expression of EGR1 and IL4 and also blocked MAPK activation in activated MCs. A variety of established medicines, including omeprazole (proton pump inhibitor)[7], tozasertib[52], and berberine (adenosine monophosphate-activated protein kinase stimulator)[53] inhibit MC activation-associated MAPK signaling. Meanwhile, T-5224 did not affect maturation of precursor cells into MCs (Figure S5). Together, these data support exploration of T-5224 for potential repurposing as a MC activation inhibitor. We proceeded to conduct in vivo studies in murine models of allergic disease employing doses appropriate for clinical application (30–300 mg/kg).

Previously, oral administration of T-5224 (30 mg/kg per day for 3 wks) was shown to resolve collagen-induced arthritis in a preclinical model[47]. Additionally, oral administration of T-5224 (300 mg/kg) has been shown to ameliorate lipopolysaccharide-induced liver/kidney injury in mice through a mechanism that involves reducing production of proinflammatory cytokines[48, 49]. T-5224 was developed into a potential therapeutic agent for rheumatoid arthritis and has advanced into phase-II clinical trials[54]. The major metabolites of T-5224, glucuronides, occur predominantly in the liver[55]. The T-5224 treatments employed in our PCA and ASA model mice, which translate to a 60-mg/kg dose, showed robust effectiveness without signs of cytotoxicity. We proceeded to test T-5224’s ability to suppress MC activation in a model of atopic dermatitis, which is characterized by MC activation and intra-dermal infiltration of MCs that release vasoactive and proinflammatory mediators[56, 57]. T-5224 attenuated MC and eosinophil infiltration in OXA-induced allergic skin, consistent with a protective effect against allergic dermatitis.

In conclusion, the present experiments demonstrated a previously unknown molecular mechanism whereby IgE/Ag promotes MC activation via a c-Fos/Egr1/IL4 axis. The c-Fos/AP1 inhibitor T-5224 reduced MC degranulation and cytokine production and attenuated allergic responses in vivo. The ability of T-5224 to inhibit MC degranulation and allergic disease presentation suggest that it should be considered as a candidate for repurposing into an allergic/inflammatory disease pharmacotherapy. Clinical trials aimed at determining the anti-allergy efficacy and toxicity of T-5224 are warranted.

**Abbreviations**

AD, atopic dermatitis; Ag, antigen; AP-1, activator protein 1; ASA, active systemic anaphylaxis; BMMC, bone marrow-derived mast cell; DNP, dinitrophenol; Egr 1, early growth response factor 1; ERK1/2, extracellular signal-regulated kinase 1/2; FITC, fluorescein isothiocyanate; FcεRI, high-affinity IgE Fc receptor; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HSA, human serum albumin; Ig, immunoglobulin; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MC, mast cell; OVA, ovalbumin; OXA, oxazolone; PCA, passive cutaneous anaphylaxis.
Declarations

Ethics approval and consent to participate

All studies involving mice were performed according to protocols approved by the Animal Care and Use Committee of the School of Medicine of Shenzhen University.

Consent for publication

Not applicable.

Availability of data and material

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Funding

The present study was supported in part by research funding from the National Natural Science Foundation of China (Grants No. 81571570 and 82071806), SZU Top Ranking Project (Grant No. 86000000210) and Shenzhen City (Grants No. JSGG20200102165803939 and JSGG20200225151806035).

Authors’ contributions

H. -N. W and L. -N. Z performed the experiments. H. -N. W, W. -Y. L and C. -C. X contributed to the data analysis. K. -M. J and J. -J. C supervised the projects and participated in experimental design and technical discussions. H. -N. W and J. -J. C wrote the draft of the manuscript. Z. -F. Z and K. -M. J revised the manuscript.

Acknowledgements

We thank the other members of Ji Kunmei lab for their critical comments.

References

1. Platts-Mills TA: The allergy epidemics: 1870-2010. J Allergy Clin Immunol 2015, 136:3-13.
2. Kim DK, Kim HS, Kim AR, Kim JH, Kim B, Noh G, Kim HS, Beaven MA, Kim YM, Choi WS: DJ-1 regulates mast cell activation and IgE-mediated allergic responses. J Allergy Clin Immunol 2013, 131:1653-1662.
3. Stone KD, Prussin C, Metcalfe DD: IgE, mast cells, basophils, and eosinophils. *J Allergy Clin Immunol* 2010, 125:S73-80.

4. Galli SJ, Tsai M: IgE and mast cells in allergic disease. *Nat Med* 2012, 18:693-704.

5. Kitaura J, Asai K, Maeda-Yamamoto M, Kawakami Y, Kikkawa U, Kawakami T: Akt-dependent cytokine production in mast cells. *J Exp Med* 2000, 192:729-740.

6. Kuehn HS, Swindle EJ, Kim MS, Beaven MA, Metcalfe DD, Gilfillan AM: The phosphoinositide 3-kinase-dependent activation of Btk is required for optimal eicosanoid production and generation of reactive oxygen species in antigen-stimulated mast cells. *J Immunol* 2008, 181:7706-7712.

7. Kanagaratham C, El Ansari YS, Sallis BF, Hollister BA, Lewis OL, Minnicozzi SC, Oyoshi MK, Rosen R, Nurko S, Fiebiger E, Oettgen HC: Omeprazole inhibits IgE-mediated mast cell activation and allergic inflammation induced by ingested allergen in mice. *J Allergy Clin Immunol* 2020, 146:884-893.e885.

8. Siraganian RP: Mast cell signal transduction from the high-affinity IgE receptor. *Curr Opin Immunol* 2003, 15:639-646.

9. Tsang F, Fred Wong WS: Inhibitors of tyrosine kinase signaling cascade attenuated antigen challenge of guinea-pig airways in vitro. *Am J Respir Crit Care Med* 2000, 162:126-133.

10. Rivera J, Gilfillan AM: Molecular regulation of mast cell activation. *J Allergy Clin Immunol* 2006, 117:1214-1225; quiz 1226.

11. Jin F, Li X, Deng Y, Timilshina M, Huang B, Kim DY, Chang JH, Ichinose H, Baek SH, Murakami M, et al: The orphan nuclear receptor NR4A1 promotes FcepsilonRI-stimulated mast cell activation and anaphylaxis by counteracting the inhibitory LKB1/AMPK axis. *Allergy* 2019, 74:1145-1156.

12. Yang YJ, Chen W, Edgar A, Li B, Molkentin JD, Berman JN, Lin TJ: Rcan1 negatively regulates FcepsilonRI-mediated signaling and mast cell function. *J Exp Med* 2009, 206:195-207.

13. Lee YN, Tuckerman J, Nechushtan H, Schutz G, Razin E, Angel P: c-Fos as a regulator of degranulation and cytokine production in FcepsilonRI-activated mast cells. *J Immunol* 2004, 173:2571-2577.

14. Wagner EF: Bone development and inflammatory disease is regulated by AP-1 (Fos/Jun). *Ann Rheum Dis* 2010, 69 Suppl 1:i86-88.

15. Baranes D, Razin E: Protein kinase C regulates proliferation of mast cells and the expression of the mRNAs of fos and jun proto-oncogenes during activation by IgE-Ag or calcium ionophore A23187. *Blood* 1991, 78:2354-2364.

16. Koga K, Takaesu G, Yoshida R, Nakaya M, Kobayashi T, Kinjyo I, Yoshimura A: Cyclic adenosine monophosphate suppresses the transcription of proinflammatory cytokines via the phosphorylated c-Fos protein. *Immunity* 2009, 30:372-383.

17. Sivalenka RR, Sinha M, Jessberger R: SWAP-70 regulates mast cell FcepsilonRI-mediated signaling and anaphylaxis. *Eur J Immunol* 2008, 38:841-854.

18. MacNeil AJ, Junkins RD, Wu Z, Lin TJ: Stem cell factor induces AP-1-dependent mast cell IL-6 production via MAPK kinase 3 activity. *J Leukoc Biol* 2014, 95:903-915.
19. Weng Z, Patel AB, Panagiotidou S, Theoharides TC: The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells. *J Allergy Clin Immunol* 2015, 135:1044-1052 e1045.

20. Ochi H, De Jesus NH, Hsieh FH, Austen KF, Boyce JA: IL-4 and -5 prime human mast cells for different profiles of IgE-dependent cytokine production. *Proc Natl Acad Sci U S A* 2000, 97:10509-10513.

21. MacNeil AJ, Yang YJ, Lin TJ: MAPK kinase 3 specifically regulates Fc epsilonRI-mediated IL-4 production by mast cells. *J Immunol* 2011, 187:3374-3382.

22. Hou YB, Ji K, Sun YT, Zhang LN, Chen JJ: CDK4/6 inhibitor palbociclib suppresses IgE-mediated mast cell activation. *J Transl Med* 2019, 17:276.

23. Kim YY, Hur G, Lee SW, Lee SJ, Lee S, Kim SH, Rho MC: AGK2 ameliorates mast cell-mediated allergic airway inflammation and fibrosis by inhibiting Fc epsilonRI/TGF-beta signaling pathway. *Pharmacol Res* 2020, 159:105027.

24. Natarajan KN, Miao Z, Jiang M, Huang X, Zhou H, Xie J, Wang C, Qin S, Zhao Z, Wu L, et al: Comparative analysis of sequencing technologies for single-cell transcriptomics. *Genome Biol* 2019, 20:70.

25. Li R, Li Y, Kristiansen K, Wang J: SOAP: short oligonucleotide alignment program. *Bioinformatics* 2008, 24:713-714.

26. Kim D, Langmead B, Salzberg SL: HISAT: a fast spliced aligner with low memory requirements. *Nat Methods* 2015, 12:357-360.

27. Li B, Dewey CN: RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. *BMC Bioinformatics* 2011, 12:323.

28. Love MI, Huber W, Anders S: Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* 2014, 15:550.

29. Lee JH, Kim JW, Ko NY, Mun SH, Her E, Kim BK, Han JW, Lee HY, Beaven MA, Kim YM, Choi WS: Curcumin, a constituent of curry, suppresses IgE-mediated allergic response and mast cell activation at the level of Syk. *J Allergy Clin Immunol* 2008, 121:1225-1231.

30. Fu Y, Wang J, Panangipalli G, Ulrich BJ, Koh B, Xu C, Kharwadkar R, Chu X, Wang Y, Gao H, et al: STAT5 promotes accessibility and is required for BATF-mediated plasticity at the Il9 locus. *Nat Commun* 2020, 11:4882.

31. Wechsler JB, Hsu CL, Bryce PJ: IgE-mediated mast cell responses are inhibited by thymol-mediated, activation-induced cell death in skin inflammation. *J Allergy Clin Immunol* 2014, 133:1735-1743.

32. Kim YY, Je IG, Kim MJ, Kang BC, Choi YA, Baek MC, Lee B, Choi JK, Park HR, Shin TY, et al: 2-Hydroxy-3-methoxybenzoic acid attenuates mast cell-mediated allergic reaction in mice via modulation of the Fc epsilonRI signaling pathway. *Acta Pharmacol Sin* 2017, 38:90-99.

33. Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD: Atopic dermatitis. *Nat Rev Dis Primers* 2018, 4:1.

34. Fujita T, Fujimoto M, Matsushita T, Shimada Y, Hasegawa M, Kuwano Y, Ogawa F, Takehara K, Sato S: Phase-dependent roles of E-selectin during chronic contact hypersensitivity responses. *Am J*
35. Joseph LB, Composto GM, Perez RM, Kim HD, Casillas RP, Heindel ND, Young SC, Lacey CJ, Saxena J, Guillon CD, et al: **Sulfur mustard induced mast cell degranulation in mouse skin is inhibited by a novel anti-inflammatory and anticholinergic bifunctional prodrug.** *Toxicol Lett* 2018, **293**:77-81.

36. Gonzalez-de-Olano D, Alvarez-Twose I: **Mast Cells as Key Players in Allergy and Inflammation.** *J Investig Allergol Clin Immunol* 2018, **28**:365-378.

37. Gangwar RS, Landolina N, Arpinati L, Levi-Schaffer F: **Mast cell and eosinophil surface receptors as targets for anti-allergic therapy.** *Pharmacol Ther* 2017, **170**:37-63.

38. Li B, Berman J, Tang JT, Lin TJ: **The early growth response factor-1 is involved in stem cell factor (SCF)-induced interleukin 13 production by mast cells, but is dispensable for SCF-dependent mast cell growth.** *J Biol Chem* 2007, **282**:22573-22581.

39. Li B, Power MR, Lin TJ: **De novo synthesis of early growth response factor-1 is required for the full responsiveness of mast cells to produce TNF and IL-13 by IgE and antigen stimulation.** *Blood* 2006, **107**:2814-2820.

40. Bischoff SC, Sellge G, Lorentz A, Sebald W, Raab R, Manns MP: **IL-4 enhances proliferation and mediator release in mature human mast cells.** *Proc Natl Acad Sci U S A* 1999, **96**:8080-8085.

41. Galli SJ, Tsai M, Piliponsky AM: **The development of allergic inflammation.** *Nature* 2008, **454**:445-454.

42. Wynn TA: **Type 2 cytokines: mechanisms and therapeutic strategies.** *Nat Rev Immunol* 2015, **15**:271-282.

43. Desmet C, Gosset P, Henry E, Garze V, Faisca P, Vos N, Jaspar F, Melotte D, Lambrecht B, Desmecht D, et al: **Treatment of experimental asthma by decoy-mediated local inhibition of activator protein-1.** *Am J Respir Crit Care Med* 2005, **172**:671-678.

44. Nguyen C, Teo JL, Matsuda A, Eguchi M, Chi EY, Henderson WR, Jr., Kahn M: **Chemogenomic identification of Ref-1/AP-1 as a therapeutic target for asthma.** *Proc Natl Acad Sci U S A* 2003, **100**:1169-1173.

45. Angel P, Szabowski A: **Function of AP-1 target genes in mesenchymal–epithelial cross-talk in skin.** *Biochemical Pharmacology* 2002, **64**:949-956.

46. Li Y, Gao J, Kamran M, Harmacek L, Danhorn T, Leach SM, O’Connor BP, Hagman JR, Huang H: **GATA2 regulates mast cell identity and responsiveness to antigenic stimulation by promoting chromatin remodeling at super-enhancers.** *Nat Commun* 2021, **12**:494.

47. Aikawa Y, Morimoto K, Yamamoto T, Chaki H, Hashiramoto A, Narita H, Hirono S, Shiozawa S: **Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1.** *Nat Biotechnol* 2008, **26**:817-823.

48. Ishida M, Ueki M, Morishita J, Ueno M, Shiozawa S, Maekawa N: **T-5224, a selective inhibitor of c-Fos/activator protein-1, improves survival by inhibiting serum high mobility group box-1 in lethal lipopolysaccharide-induced acute kidney injury model.** *J Intensive Care* 2015, **3**:49.
49. Izuta S, Ueki M, Ueno M, Nishina K, Shiozawa S, Maekawa N: T-5224, a selective inhibitor of c-Fos/activator protein-1, attenuates lipopolysaccharide-induced liver injury in mice. Biotechnol Lett 2012, 34:2175-2182.

50. Makino H, Seki S, Yahara Y, Shiozawa S, Aikawa Y, Motomura H, Nogami M, Watanabe K, Sainoh T, Ito H, et al: A selective inhibition of c-Fos/activator protein-1 as a potential therapeutic target for intervertebral disc degeneration and associated pain. Sci Rep 2017, 7:16983.

51. Tanaka S, Ishii T, Sato T, Toi M, Itou J: Eribulin mesylate-induced c-Fos upregulation enhances cell survival in breast cancer cell lines. Biochem Biophys Res Commun 2020, 526:154-157.

52. Zhang LN, Ji K, Sun YT, Hou YB, Chen JJ: Aurora kinase inhibitor tozasertib suppresses mast cell activation in vitro and in vivo. Br J Pharmacol 2020, 177:2848-2859.

53. Fu S, Ni S, Wang D, Fu M, Hong T: Berberine suppresses mast cell-mediated allergic responses via regulating FcεRI-mediated and MAPK signaling. Int Immunopharmacol 2019, 71:1-6.

54. Ye N, Ding Y, Wild C, Shen Q, Zhou J: Small molecule inhibitors targeting activator protein 1 (AP-1). J Med Chem 2014, 57:6930-6948.

55. Uchihashi S, Fukumoto H, Onoda M, Hayakawa H, Ikushiro S, Sakaki T: Metabolism of the c-Fos/activator protein-1 inhibitor T-5224 by multiple human UDP-glucuronosyltransferase isoforms. Drug Metab Dispos 2011, 39:803-813.

56. Gupta K, Harvima IT: Mast cell-neural interactions contribute to pain and itch. Immunol Rev 2018, 282:168-187.

57. Nakamura Y, Oscherwitz J, Cease KB, Chan SM, Muñoz-Planillo R, Hasegawa M, Villaruz AE, Cheung GY, McGavin MJ, Travers JB, et al: Staphylococcus δ-toxin induces allergic skin disease by activating mast cells. Nature 2013, 503:397-401.